การประเมินความคุ้มค่าแบบ Distributional Cost-Effectiveness Analysis (DCEA) เป็นการประเมินความคุ้มค่ารูปแบบใหม่ ที่ผนวกประเด็นความไม่เสมอภาค เข้าเป็นส่วน

There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This study conducts the evidence synthesis to inform policy decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of bevacizumab for the treatment of

การจัดกระบวนการพัฒนาชุดสิทธิประโยชน์แบบครบวงจร ภายใต้ระบบหลักประกันสุขภาพแห่งชาติ เป็นการดำเนินงานตามที่ได้รับมอบหมายจ

101-201-2553

The abundance of various innovations in healthcare (pharmaceuticals, medical devices, interventions, individual and community health promotion and disease prevention as well as a social health policy) have been continuously used in the healthcare system, resulting in a higher demand for resources and budgets in disease prevention and healthcare. Th

There is an increasing impetus to use economic evaluation to allow more explicit and transparent healthcare priority setting. However, an important question for policy makers is whether it is appropriate and feasible to introduce economic evaluation data into healthcare priority setting or resource allocation decisions. This project systematically

Over the past two decades a notable progression has been made in relation to the capacity building of health technology assessment (HTA ) research and its policy utility in Thailand. Such developments have been shaped by multiple factors. This study aims to review 20 years experiences of an attempt to establish a  formal HTA system in Thailand, fo

A number of collaborative works between MoPH hospitals and the private sector were observed. Health services collaboration is the most obvious and popular model adopted by many MoPH hospitals. Until now, these has been no clear policy regarding such collaborations and this has led to drawbacks. Authors proposed a collaborative framework should be c